התמחויות

Two-Dose Zenapax Reduced Incidence Of Acute Organ Rejection in Kidney Transplant

ATC: New Investigational Study Reports Two-Dose Zenapax Reduced Incidence Of Acute Organ Rejection in Kidney Transplant Recipients At High Risk for Delayed Organ Function

WASHINGTON, DC — May 9, 2002 — Two-doses of the immunosuppressive agent Zenapax® (daclizumab) decreased rejection in kidney transplant patients at high risk for delayed organ function, and had cost benefits when compared to OKT3 (muromonab-CD3), another induction treatment used to prevent acute organ rejection, according to a new investigational study comparing the two treatments that was reported at the American Transplant Congress, a joint meeting held annually by the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS).

Transplantation of kidneys that are not considered fully functional, based on criteria such as prolonged time to transplantation, places patients at increased risk for delayed organ function. According to the United Network for Organ Sharing (UNOS), 21 percent of kidney transplant recipients between 1991 and 1998 experienced delayed function of their transplanted organ. While the use of marginal organs increases the pool of available organs, it is also associated with an increased risk of rejection and increased cost because of the higher likelihood the organ will function poorly or not at all immediately after the transplant.

“Preventing organ rejection is the key to transplant success and brings us closer to finding a way to decrease the need for re-transplantation and increase our organ supply,” said investigator, Benjamin Philosophe, M.D., Ph.D., a transplant surgeon at the University of Maryland Medical Center and assistant professor at the University of Maryland School of Medicine, Baltimore, MD.


לכתבה המלאה

תגובות רוצה להצטרף לדיון?

אין תגובות עדיין. היה הראשון להגיב!

מאמרים

לכל המאמרים

כניסת צוות רפואי

הכניסה לאתר מותרת אך ורק לצוות הרפואי

לקבלת קוד אימות לנייד ולמייל, יש למלא את כתובת המייל ואת מספר הטלפון שלך

עדיין לא נרשמת? באפשרותך לבצע רישום כאן